Congestive Heart Failure (CHF) - Epidemiology Forecast - 2032

DelveInsight’s ""Congestive Heart Failure (CHF) - Market Insights, Epidemiology, and Market Forecast—2032" report delivers an in-depth understanding of the CHF, historical and forecasted CHF epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

CHF Disease Understanding

Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right- side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes the shortness of breath and fatigue (tiredness) and the right-side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.

The body depends on the heart to pump and deliver oxygen and nutrient-rich blood to every cell. When the cells are nourished accurately, the body gains the ability to work normally. With HF, the weakened heart is not able to supply nutrients to the cells with enough blood which results in fatigue and shortness of breath and some people coughing.

HF is triggered by structural and functional limitations in the myocardium resulting in damage of ventricular filling or the ejection of blood by the heart. The most common cause for HF is lowering of the left ventricular myocardial utility along with the dysfunction of pericardium, myocardium, endocardium, heart valves or large vessels alone or in the combination. Some of the major pathogenic mechanisms leading to HF are excessive neurohumoral stimulation, irregular myocyte calcium cycling, augmented hemodynamic overload, ischemic dysfunction, ventricular remodeling, extreme or inadequate production of the extracellular matrix, enhanced apoptosis and genetic mutations.

The signs and symptoms of HF are subtle at the initial stage, and these are generally misguided for common signs of aging. The common symptoms of HF are because of the extra fluid or congestion which leads to blocking of the vessels. The starting of the congestion in the lungs is carry forwarded to the different parts of the body.

Patients with heart failure can present with a challenging array of comorbid medical conditions. GPs have an important role in recognizing and managing these, to ensure that heart failure therapies are not compromised and that only necessary medications are prescribed.

CHF Epidemiology

The CHF epidemiology division provides insights about historical and current CHF patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted CHF epidemiology [segmented as total prevalent cases of CHF, total diagnosed prevalent cases of CHF, age-specific prevalence of CHF, gender-specific cases of CHF, NYHA class-specific diagnosed prevalent cases of CHF, diagnosed prevalent cases of Heart Failure with Ejection Fraction cases of CHF and diagnosed prevalent cases of Heart Failure associated with comorbidities cases of CHF in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise CHF Epidemiology

Estimates show that the highest cases of CHF in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, Italy, France, and Spain in the year 2021.
The total prevalent cases of Heart Failure in 2021 in the 7MM were estimated to be 16,630,560, out of which the highest prevalent cases of this disease were seen in the United States i.e. 6,543,570.
As per the DelveInsight analysis, the total diagnosed prevalent cases of HF in Japan were found to be 894,093 cases in 2021 which are expected to increase during the study period.
According to the analysis, in 2021, the estimated cases of HF were 2,512,731 in males and 2,722,125 in females in the US
In 2021, the United States accounted for 157,569, 261,743, 729,215, 1,204,017, 1,630,259 and 1,252,053 for the age group <44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years and ≥85 years.
In 2021, the estimated cases of Heart failure with preserved and medium ejection fraction (HFpEF and HFmEF) and Heart failure with reduced ejection fraction (HFrEF) were 3,140,914 and 2,093,942 respectively in the US.
There were 2,669,777, 1,533,813, 523,486, and 523,486 cases respectively, of NHYA-class I, class II, class III and class IV, in the US in 2021.
As per the estimates in 2021, 3,891,069, 2,268,263, 1,005,092, 1,648,980, 1,609,718, 3,140,914 and 2,093,942 cases were observed in Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Atrial Fibrillation, COPD, Ischemic heart disease and dilated cardiomyopathy.
The total diagnosed prevalent cases of HF in EU5 were found to be 6,671,149 cases in 2021. Among the EU5 countries, the highest diagnosed prevalent cases of Heart Failure was found to be in Germany with 2,258,512 cases, followed by Spain with 1,305,726 cases in 2021. On the other hand, the UK had the least diagnosed prevalent cases of Heart Failure, with 741,205 cases in 2021. These numbers are expected to increase during the study period (2019-2032).
As per DelveInsight estimates, Japan accounted for 1,192,124 prevalent cases of CHF in 2021.

Scope of the Report
The report covers the descriptive overview of CHF, explaining its causes, signs and symptoms, pathophysiology, and diagnosis.
Comprehensive insight has been provided into the CHF epidemiology in the 7MM
A detailed review of CHF market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CHF market

Report Highlights
In the coming years, CHF market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence CHF R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for CHF. Launch of emerging therapies will significantly impact the CHF market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CHF
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

CHF Report Insights
Patient Population
Therapeutic Approaches
CHF Pipeline Analysis
CHF Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

CHF Report Key Strengths
11 Years Forecast
7MM Coverage
CHF Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

CHF Report Assessment
Disease Understanding
Current Diagosis Practices and Guidelines
Epidemiology Trends

Key Questions

Epidemiology Insights:
What is the disease risk, burden and regional/ethnic differences of the CHF?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical CHF patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of CHF in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHF?
Out of all CHF countries, which country would have the highest prevalent population of CHF during the forecast period (2019-2032)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the CHF market
To understand the future market competition in the CHF market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for CHF in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for CHF market
To understand the future market competition in the CHF market